g12c

K-Ras(G12C) inhibitor 12 is an allosteric inhibitor of the oncogenic K-Ras(G12C) protein.

KRAS G12C inhibitor 16 is a potent inhibitor of KRAS G12C.

KRas G12C inhibitor 1 is a compound that selectively inhibits the KRas G12C protein.

K-Ras G12C-IN-4, is a potent Covalent Inhibitor of KRASG12C..

K-Ras(G12C) inhibitor 6 is an irreversible, allosteric inhibitor of the K-Ras(G12C) mutant, achieving 100% protein modification at 10 μM after 24 hours in vitro.

KRAS G12C inhibitor 43 is a potent inhibitor of KRAS G12C and inhibits the migration and proliferation of H358 cells (IC50: 0.001-1 μM μM), A549 cells (IC50>1 μM) and HCC cells (IC50>1 μM).

KRas G12C inhibitor 4 is a compound that inhibits KRas G12C.

KRAS G12C inhibitor 22 is a specific inhibitor of the KRAS G12C mutation.

PROTAC KRAS G12C Degrader-3 (Comp 283) serves as a potent degrader of KRAS G12C, utilized in cancer research [1].

KRAS G12C Inhibitor 37, a potent inhibitor of KRAS G12C, targets the Ras family of proteins, crucial for intracellular signaling related to growth and development. This compound holds potential for research into cancers mediated by KRAS G12C.

KRAS G12C inhibitor 20 is an inhibitor specifically targeting the KRAS G12C mutation.

KRAS G12C inhibitor 34 is an inhibitor of KRAS G12C that can be used to study cancer research.

KRas G12C inhibitor 3 is a compound that specifically inhibits the KRas G12C mutation.

KRAS G12C inhibitor 21 is a specific inhibitor targeting the KRAS G12C mutation.

Heterocyclic compounds as covalent inhibitors of G12C mutant K-Ras protein useful for treating cancers.K-Ras G12C-IN-3 is a novel and irreversible inhibitor of mutant K-ras G12C.

KRAS G12C inhibitor 49 is an orally active KRAS G12C inhibitor that exhibits antitumour effects.

K-Ras G12C-IN-1 is a novel, irreversible inhibitor of mutant K-Ras G12C.

KRAS G12C inhibitor 50 is a KRAS G12C inhibitor (IC50: 46.7 nM).

KRAS G12C Inhibitor 35 is a potent suppressor of KRAS G12C, targeting a crucial member of the Ras protein family which significantly impacts cellular growth and development. This compound holds promise for investigating cancer driven by KRAS G12C mutations.

KRAS G12C Inhibitor 39, a potent antagonist, specifically targets the KRAS G12C mutation, a prime focus in pharmaceutical cancer research. This compound shows promise for investigating KRAS G12C-mediated cancer.

KRAS G12C Inhibitor 41 is a potent agent targeting the KRAS G12C mutation within the Ras family of proteins, which are crucial for intracellular signaling related to growth and development. This compound holds significant potential for advancing research in cancers mediated by KRAS G12C.

KRAS G12C Inhibitor 48 is a potent inhibitor targeting the KRAS G12C mutation, exhibiting an IC50 value of 639.91 nM. Demonstrating antiproliferative activity, KRAS G12C Inhibitor 48 (0-50 µM) yields IC50 values of 0.796 µM, 6.33 µM, and 16.14 µM against H358, H23, and A549 cell lines, respectively.

KRAS G12C inhibitor 17 is a potent inhibitor of the KRAS G12C protein.

KRAS G12C inhibitor 44 is a potent, orally active KRAS G12C inhibitor. KRAS G12C inhibitor 44 exhibits anti-proliferative effects in MIA PaCA-2 (IC50: 0.016 μM), H358 cells (IC50: 0.028 μM). inhibitor 44 has anti-tumour activity in vivo.

K-Ras G12C-IN-2 is a covalent KRAS G12C inhibitor.

PROTAC KRAS G12C degrader-1, a cereblon-based degrader, promotes CRBN/KRAS G12C dimerization and facilitates the degradation of GFP-KRAS G12C in reporter cells [1].

KRAS G12C inhibitor 33 is a KRAS G12C inhibitor used in cancer research.

KRAS G12C inhibitor 61 (Example 3) demonstrates potent activity by inhibiting phospho-ERK 1 2 in MIA PaCa-2 cells, with an IC50 value of 9 nM, and is applicable in the research of pancreatic, colorectal, and lung cancers [1].

KRAS G12C inhibitor 46 is a potent inhibitor of KRAS G12C.

KRAS G12C inhibitor 15 is a potent inhibitor of the KRAS G12C protein.

KRAS G12C Inhibitor 28 is a compound that effectively inhibits the KRAS G12C mutation, exhibiting potent antitumor effects with an inhibitory concentration (IC50) of 57 nanomoles (nM).

KRAS G12C inhibitor 56, a powerful inhibitor of SOS1 with an inhibitory concentration (IC50) of 1.6 nM, holds promise for use in cancer research.

KRAS G12C inhibitor 30 is an inhibitor of KRAS G12C and can be used to study cancer.

KRAS G12C inhibitor 5 is a KRas G12C inhibitor. (Add a sentence that describes its primary function, mechanism, or application.)

KRAS G12C Inhibitor 60 (compound 23), a selective inhibitor targeting the Kras-G12C mutation, is utilized in the investigation of lung, colorectal, and pancreatic cancers [1].

KRAS G12C inhibitor 31 is an inhibitor of KRAS G12C that can be used to study cancer.

KRAS G12C inhibitor 45 is a potent KRAS G12C inhibitor .

KRAS G12C inhibitor 40, a potent suppressor of the KRAS G12C, targets the Ras family of intracellular signaling proteins crucial for growth and development. This compound holds significant potential for researching cancers mediated by KRAS G12C.

KRAS G12C inhibitor 53 (Compound 1) is a KRAS G12C inhibitor.

KRAS G12C inhibitor 29 is an inhibitor of KRAS G12C and can be used to study cancer.

KRAS G12C inhibitor 19 is a potent KRAS G12C inhibitor that demonstrates anti-tumor activity in cellular assays and inhibits tumor growth [1].

KRas G12C inhibitor 2 is a compound specifically designed to inhibit the KRas G12C mutation.

KRAS G12C inhibitor 1R can be used in studies about Ras.

KRAS G12C mutant protein inhibitor A-1 can be used in studies about Ras.

KRAS G12C inhibitor 18 is a potent and orally active compound that inhibits KRAS G12C, demonstrating significant anti-tumor activities.

KRAS G12C Inhibitor 59 is a compound with anticancer properties.

KRAS G12C inhibitor 58 is utilized in cancer research as an inhibitor of the KRAS G12C mutation [1].

KRAS G12C inhibitor 47 is a potent inhibitor of KRAS G12C (IC50: 0.172 μM). KRAS G12C inhibitor 47 exhibits p-ERK inhibition in MIA PaCA-2 cells, A549 cells with IC50 values of 0.046 μM and 69.8 μM respectively. KRAS G12C inhibitor 47 showed investigational potential against pancreatic, colorectal and lung cancers.

KRAS G12C Inhibitor 32, an eight-membered heterocyclic compound with nitrogen, acts as a potent inhibitor of KRAS G12C [1].

K-Ras(G12C) inhibitor 9 is an allosteric inhibitor of oncogenic K-Ras(G12C).